Nothing Special   »   [go: up one dir, main page]

NO20052362D0 - Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner - Google Patents

Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner

Info

Publication number
NO20052362D0
NO20052362D0 NO20052362A NO20052362A NO20052362D0 NO 20052362 D0 NO20052362 D0 NO 20052362D0 NO 20052362 A NO20052362 A NO 20052362A NO 20052362 A NO20052362 A NO 20052362A NO 20052362 D0 NO20052362 D0 NO 20052362D0
Authority
NO
Norway
Prior art keywords
dalbavancin
administering
treatment
methods
bacterial infections
Prior art date
Application number
NO20052362A
Other languages
English (en)
Other versions
NO20052362L (no
Inventor
Adriano Malabarba
Marco Cavaleri
Giorgio Mosconi
Daniela Jabes
Martin Stogniew
Timothy Henkel
Richard J White
Original Assignee
Vicuron Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32330046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052362(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vicuron Pharm Inc filed Critical Vicuron Pharm Inc
Publication of NO20052362D0 publication Critical patent/NO20052362D0/no
Publication of NO20052362L publication Critical patent/NO20052362L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO20052362A 2002-11-18 2005-05-12 Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner NO20052362L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42765402P 2002-11-18 2002-11-18
US48569403P 2003-07-08 2003-07-08
US49504803P 2003-08-13 2003-08-13
US49648303P 2003-08-19 2003-08-19
PCT/US2003/036127 WO2004045636A1 (en) 2002-11-18 2003-11-14 Methods of administering dalbavancin for treatment of bacterial infections

Publications (2)

Publication Number Publication Date
NO20052362D0 true NO20052362D0 (no) 2005-05-12
NO20052362L NO20052362L (no) 2005-08-17

Family

ID=32330046

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052362A NO20052362L (no) 2002-11-18 2005-05-12 Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner

Country Status (15)

Country Link
US (12) US20050130909A1 (no)
EP (1) EP1565201B1 (no)
JP (3) JP5519090B2 (no)
KR (2) KR20120056310A (no)
AU (3) AU2003299561A1 (no)
CA (1) CA2506236C (no)
DK (1) DK1565201T3 (no)
ES (1) ES2712656T3 (no)
HK (2) HK1083684A1 (no)
HU (1) HUE041133T2 (no)
IL (3) IL168327A (no)
MX (1) MXPA05005338A (no)
NO (1) NO20052362L (no)
PT (1) PT1565201T (no)
WO (3) WO2004045636A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
AU2003299561A1 (en) * 2002-11-18 2004-06-15 Vicuron Pharmaceuticals Inc. Compositions and methods for treating bacterial infections with protein-dalbavancin complexes
US20090062182A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched dalbavancin
US8389583B2 (en) * 2008-05-23 2013-03-05 Zurex Pharma, Inc. Antimicrobial compositions and methods of use
US20110132607A1 (en) * 2009-12-07 2011-06-09 Schlumberger Technology Corporation Apparatus and Technique to Communicate With a Tubing-Conveyed Perforating Gun
AU2014239965A1 (en) 2013-03-15 2015-09-24 Melinta Subsidiary Corp. Methods of treating infections in overweight and obese patients using antibiotics
CN105814352B (zh) 2013-12-19 2019-01-04 通用电气健康护理生物科学股份公司 用于生物液体加工系统的远程促动阀
NZ728401A (en) 2014-07-17 2020-08-28 The Medicines Co High purity oritavancin and method of producing same
RS61418B1 (sr) 2014-11-06 2021-03-31 Xellia Pharmaceuticals Aps Kompozicije glikopeptida
CA2978305A1 (en) * 2015-03-02 2016-09-09 Colonaryconcepts Llc Compounds and methods for peg metabolite and peg breakdown product assays
EP3978618A1 (en) 2015-05-08 2022-04-06 Spectral Platforms, Inc. Albumin-based non-covalent complexes and methods of use thereof
US20200171124A1 (en) 2016-04-15 2020-06-04 Lupin Limited Topical compositions for ophthalmic and otic use
MX2019011119A (es) 2017-03-20 2019-12-19 Spectral Platforms Inc Metodos espectroscopicos para detectar y caracterizar microorganismos.
BR112020000430A2 (pt) * 2017-07-10 2020-07-21 Contrafect Corporation potenciação em componentes san¬guíneos de atividade antibacteriana de proteína lítica e métodos e usos da mesma
CN110183519B (zh) * 2019-05-06 2023-04-11 大邦(湖南)生物制药有限公司 一种达巴万星关键中间体a40926的分离纯化方法
CN112480214B (zh) * 2020-12-14 2023-03-28 成都雅途生物技术有限公司 一种达巴万星关键中间体a40926的制备方法
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
KR20230130679A (ko) 2021-01-11 2023-09-12 셀리아 파마슈티칼즈 에이피에스 합성 방법
CN115215926A (zh) * 2022-08-12 2022-10-21 丽珠集团福州福兴医药有限公司 达巴万星母核及其纯化方法、达巴万星及其合成方法
WO2024079223A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
EP4431084A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Formulation of dalbavancin
EP4431083A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Formulation of dalbavancin

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US573679A (en) * 1896-12-22 Apparatus for mowing hay
US541616A (en) * 1895-06-25 Elevator attachment
GB1496386A (en) * 1975-03-05 1977-12-30 Lepetit Spa Antibiotics
US4195079A (en) * 1979-01-31 1980-03-25 Pfizer Inc. New polycyclic ether antibiotic
CA1183789A (en) 1981-08-04 1985-03-12 Kiyoshi Isono Antibiotic 76-11, process for the production thereof, anticoccidiosis agent and domestic animals growth accelerator comprising the same as an effective ingredient
US4578271A (en) 1982-05-24 1986-03-25 Fujisawa Pharmaceutical Co., Ltd. Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions
FI73697C (fi) * 1982-06-08 1987-11-09 Lepetit Spa Foerfarande foer framstaellning av individuella faktorer 1, 2, 3, 4 och 5 av teikomysin a2.
FR2548021B1 (fr) 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
GB8415092D0 (en) * 1984-06-13 1984-07-18 Lepetit Spa Ester derivatives
GB8425685D0 (en) * 1984-10-11 1984-11-14 Lepetit Spa Antibiotic a 40926 complex
GB8428619D0 (en) * 1984-11-13 1984-12-19 Lepetit Spa Derivatives of antibiotic l 17046
US4914187A (en) * 1984-11-13 1990-04-03 Gruppo Lepetit S.P.A Ester derivatives of antibiotic L 17046
GB8512795D0 (en) 1985-05-21 1985-06-26 Lepetit Spa Increasing ratio of components of teicoplanin a2 complex
GB8531846D0 (en) 1985-12-30 1986-02-05 Lepetit Spa Antibiotic a 40926 mannosyl aglycon
GB8608809D0 (en) * 1986-04-11 1986-05-14 Lepetit Spa Antibiotic
GB8621912D0 (en) 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GB8621911D0 (en) * 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GR871488B (en) 1986-10-10 1987-11-12 Lepetit Spa New antibiotics
GB8715735D0 (en) * 1987-07-03 1987-08-12 Lepetit Spa De-mannosyl teicoplanin derivatives
US4882313A (en) * 1987-07-31 1989-11-21 Smithkline Beckman Corporation Carboxamide derivatives of glycopeptides
GB8726859D0 (en) 1987-11-17 1987-12-23 Lepetit Spa 22-dechlorotei-coplanins
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
FR2628269B1 (fr) * 1988-03-04 1990-07-27 Sgs Thomson Microelectronics Dispositif de demarrage progressif d'une alimentation a decoupage
EP0376041B1 (en) 1988-12-27 1996-02-28 GRUPPO LEPETIT S.p.A. C63-Amide derivatives of 34-de(acetylglucosaminyl)-34-deoxy-teicoplanins
IE64155B1 (en) 1989-03-29 1995-07-12 Lepetit Spa New substituted alkylamide derivatives of teicoplanin
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
US5030619A (en) * 1990-04-16 1991-07-09 Miles Inc. Synergistic fungicidal composition
US5606036A (en) * 1991-03-27 1997-02-25 Gruppo Lepetit Spa Antibiotic A 40926 ester derivatives
JP2783722B2 (ja) * 1991-07-12 1998-08-06 麒麟麦酒株式会社 スピカマイシン誘導体およびそれを含む抗腫瘍剤
US5750509A (en) * 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
JP3418762B2 (ja) 1991-07-29 2003-06-23 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ 抗生物質ａ４０９２６のアミド誘導体類
US6384013B1 (en) * 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5882900A (en) * 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
CA2112776C (en) * 1993-01-21 2002-11-12 Masakazu Tsuchiya Process for inhibiting activity of endotoxin
DE69429617T2 (de) * 1993-04-30 2002-08-22 Biognostik Gesellschaft Fuer Biomolekulare Diagnostik Mbh Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
ES2161344T3 (es) * 1995-02-07 2001-12-01 Biosearch Italia Spa Derivados oxazolin-amidicos basicos de los antibioticos ge2270 y similares.
DK0801655T3 (da) * 1995-02-07 1999-02-08 Biosearch Italia Spa Basiske prolinamidderivater af GE 2270 og GE 2270-lignende antibiotika
SI9500039B (sl) * 1995-02-07 2002-02-28 Lek, Nov kombiniran postopek čiščenja Vankomicin hidroklorida
US5789308A (en) * 1995-06-06 1998-08-04 Advanced Micro Devices, Inc. Manufacturing method for wafer slice starting material to optimize extrinsic gettering during semiconductor fabrication
EP0750913A3 (en) * 1995-06-30 1997-11-05 Takeda Chemical Industries, Ltd. Disaccharide containing freeze-dried preparation for pharmaceutical use
WO1997002288A1 (en) * 1995-07-05 1997-01-23 Gruppo Lepetit S.P.A. Purification of dalbaheptide antibiotics by isoelectric focusing
DE19600590A1 (de) * 1996-01-10 1997-07-24 Tzn Forschung & Entwicklung Schutzvorrichtung für optische Systeme zur Vermeidung von Schäden bei Bestrahlung dieser Systeme mit Laserlicht
ATE231163T1 (de) * 1996-02-14 2003-02-15 Biosearch Italia Spa Derivate des antibiotisch wirkenden faktors ge2270
WO1997038702A1 (en) 1996-04-12 1997-10-23 Eli Lilly And Company Covalently-linked glycopeptide dimers
DE69708293T2 (de) * 1996-04-23 2002-05-02 Biosearch Italia S.P.A., Gerenzano Chemisches Verfahren zur Herstellung von Amidderivaten von A 40926 Antibiotikum
US5935238A (en) * 1997-06-19 1999-08-10 Sun Microsystems, Inc. Selection from multiple fetch addresses generated concurrently including predicted and actual target by control-flow instructions in current and previous instruction bundles
JP4204655B2 (ja) * 1997-08-08 2009-01-07 株式会社ルネサステクノロジ パルス出力機能付マイクロコンピュータ
CA2255140A1 (en) 1997-12-23 1999-06-23 Eli Lilly And Company Echinocandin binding domain of 1,3-.beta.-glucan synthase
US6541616B1 (en) * 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
US6417180B1 (en) 1998-10-07 2002-07-09 University Of Massachusetts Zinc finger-reactive antimicrobial compounds
DE69908819T2 (de) * 1998-12-23 2004-05-06 Theravance, Inc., South San Francisco Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
AU2003229475A1 (en) 2002-02-18 2003-09-09 Combinature Biopharm Ag Novel glycopeptide antibiotics and method for synthesis thereof
AU2003299561A1 (en) * 2002-11-18 2004-06-15 Vicuron Pharmaceuticals Inc. Compositions and methods for treating bacterial infections with protein-dalbavancin complexes
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections

Also Published As

Publication number Publication date
IL168327A (en) 2014-02-27
AU2003294262B2 (en) 2007-08-23
MXPA05005338A (es) 2005-12-14
ES2712656T3 (es) 2019-05-14
HK1114014A1 (en) 2008-10-24
IL239913A0 (en) 2015-08-31
US20040224908A1 (en) 2004-11-11
US20040220122A1 (en) 2004-11-04
HUE041133T2 (hu) 2019-05-28
US20050130914A1 (en) 2005-06-16
NO20052362L (no) 2005-08-17
WO2004046196A2 (en) 2004-06-03
US6900175B2 (en) 2005-05-31
US20050130909A1 (en) 2005-06-16
US20050004011A1 (en) 2005-01-06
WO2004045637A1 (en) 2004-06-03
JP2013155188A (ja) 2013-08-15
KR20120056310A (ko) 2012-06-01
US20040198715A1 (en) 2004-10-07
PT1565201T (pt) 2019-02-05
CA2506236A1 (en) 2004-06-03
US7115564B2 (en) 2006-10-03
KR101173310B1 (ko) 2012-08-10
EP1565201B1 (en) 2018-10-31
CA2506236C (en) 2018-07-17
KR20050094396A (ko) 2005-09-27
JP5519090B2 (ja) 2014-06-11
IL230875A0 (en) 2014-03-31
IL239913B (en) 2019-01-31
US20040142883A1 (en) 2004-07-22
AU2003298662A1 (en) 2004-06-15
JP2006514092A (ja) 2006-04-27
AU2003299561A1 (en) 2004-06-15
WO2004046196A3 (en) 2004-08-19
US20050032721A1 (en) 2005-02-10
US20090298748A1 (en) 2009-12-03
HK1083684A1 (en) 2006-07-07
EP1565201A1 (en) 2005-08-24
WO2004045636A1 (en) 2004-06-03
AU2003294262A1 (en) 2004-06-15
US20040197415A1 (en) 2004-10-07
JP2011157381A (ja) 2011-08-18
US20090305953A1 (en) 2009-12-10
DK1565201T3 (en) 2019-02-25
US20050090433A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
NO20052362D0 (no) Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner
DE60327438D1 (de) Amino-substituierte cyclohexan derivate zur behandlung bakterieller infektionen
CY2019030I2 (el) Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
NO20044054L (no) Administrering av midler for behandling av betennelse
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
GB0125222D0 (en) Composition for the treatment of microbial infections
PL376454A1 (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections
AU2003901008A0 (en) Composition for the treatment and prevention of bacterial infections
ZA200507070B (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
NO20052580D0 (no) Blandinger for behandling av infeksjon av Flavivirida viruser
EP1594444A3 (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
IL187904A (en) Use of quinoline derivatives for the preparation of bacterial preparations for the treatment of bacteria caused by bacteria
EP1531828A4 (en) METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES
NO20055010D0 (no) Preparater inneholdende laktulose for behandling av potavirusinfeksjoner
GB0329254D0 (en) Treatment of viral infections
NO20043445L (no) Kombinasjonsterapi for behandling av bakterielle infeksjoner
EP1626692A4 (en) COMPOUNDS FOR TREATING FLAVIVIRUS INFECTIONS
ATE528004T1 (de) Chinolon-antibiotika zur behandlung von periodontaler infektionen
IL180459A0 (en) Treatment of bacterial infections
AU2003291886A1 (en) Thiophenederivatives for the treatment of flavivirus infections
PL374524A1 (en) Composition based on triethyl citrate for the treatment of bacterial infections of the skin
GB0329958D0 (en) Treatment of viral infections
NO20052814D0 (no) Cytomodulerende peptider for behandling av interstitielle cystitt
AU2003240545A1 (en) Use of ramoplanin to treat diseases associated with the use of antibiotics
AU2003258983A8 (en) Combinations for the treatment of fungal infections

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application